PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Kedudukan dalam Saham #1439
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Harga Saham
$36.89
Modal Pasaran
$15.25B
Perubahan (1 hari)
-1.28%
Perubahan (1 tahun)
144.12%
Negara
TW
Perdagangan PharmaEssentia Corporation (6446)

Kategori

Healthcare
Bilangan saham terbitan bagi PharmaEssentia Corporation (6446)
Bilangan saham terbitan setakat June 2026: 504.54M
Menurut laporan kewangan terkini dan harga saham PharmaEssentia Corporation, bilangan saham terbitan semasa ialah 504.54M. Pada akhir December 2023, syarikat mempunyai 357.63M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk PharmaEssentia Corporation (6446) dari 2010 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
2026 (TTM) 504.54M 39.70%
2024 361.15M 0.98%
2023 357.63M 13.47%
2022 315.19M 9.24%
2021 288.52M 6.05%
2020 272.06M 11.95%
2019 243.02M -2.49%
2018 249.23M 0.35%
2017 248.36M 6.59%
2016 233.00M 7.71%
2015 216.33M 0.61%
2014 215.01M 7.64%
2013 199.75M 37.81%
2012 144.95M 4.85%
2011 138.25M 0.00%
2010 138.25M 0.00%
Saham terbitan bagi syarikat atau pesaing yang serupa